摘要
肿瘤治疗的个体化带来了临床实践变革。近年来,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)对EGFR阳性突变的非小细胞肺癌显示出良好的抗肿瘤活性。第三代EGFR-TKIs相对于一代EGFR-TKI,显著提高了EGFR突变晚期非小细胞肺癌治疗的有效率、无进展生存期及总生存期,且对脑转移病灶有良好的疗效,对可手术的EGFR突变非小细胞肺癌术后辅助治疗也体现了无病生存获益,在联合放疗应用于局部晚期及晚期寡转移EGFR突变非小细胞肺癌中优势明显。
The individualization of cancer treatment has brought about revolution in clinical practice.In recent years,EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation.Compared with the first-generation EGFR-TKI,the third-generation EGFR-TKI significantly increased the effective rate,progression-free survival and overall survival of advanced non-small cell lung cancer with EGFR mutation,especially the brain metastases.And the third-generation EGFR-TKI also showed the benefits of disease-free survival as the post-operative adjuvant therapy for operable EGFR-mutated nonsmall cell lung cancer.Moreover,the third-generation EGFR-TKI in combination with radiotherapy showed obvious advantages in the treatment of locally advanced and advanced oligometastatic EGFR-mutated nonsmall cell lung cancer.
作者
许雯雯
朱宇熹
XU Wenwen;ZHU Yuxi(Department of Oncology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China;Department of Oncology,Jinshan Hospital,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China)
出处
《肿瘤防治研究》
CAS
CSCD
2021年第12期1129-1134,共6页
Cancer Research on Prevention and Treatment
